You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 基石藥業-B(2626.HK)高開近5% 預計2022年收入總額翻番 虧損減半
格隆匯 02-03 09:28
格隆匯2月3日丨基石藥業-B(2626.HK)高開近5%,報5.56港元,創2022年7月11日以來新高,總市值66億港元。該公司昨日盤後公佈,集團截至2022年12月31日止年度的收入總額預期將不少於人民幣4.750億元,較截至2021年12月31日止年度的收入約人民幣2.437億元幾乎翻了一番。集團截至2022年12月31日止年度不包括以股份為基礎的付款開支的年度虧損預期將不超過人民幣8億元,較截至2021年12月31日止年度的約人民幣16.974億元大幅減少不低於53%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account